Advertisement
AMRN vs MGNX
Which Stock Would AI Choose? Amarin Corporation plc (AMRN) vs. MacroGenics, Inc. (MGNX) Stock Comparison
Key Takeaways
- AMRN is a commercial-stage cardiovascular drugmaker generating positive operating cash flow, while MGNX is a clinical-stage oncology biotech still reporting net losses.
- Amarin's sole product, Vascepa/Vazkepa, faces generic erosion in the U.S., whereas MacroGenics relies on partnered royalties and a maturing antibody-drug conjugate (ADC) pipeline.
- MacroGenics has delivered stronger year-to-date price gains but has pulled back sharply in recent weeks, while Amarin has traded in a comparatively narrow range.
- Both companies are restructuring: Amarin is cutting its workforce to lower costs, and MacroGenics is divesting manufacturing to extend its cash runway.
- Risk profiles differ materially—Amarin's risk centers on single-product concentration, while MacroGenics' centers on binary clinical trial outcomes.
Introduction
Investors comparing AMRN and MGNX are effectively weighing two very different risk-and-return profiles within the pharmaceutical and biotechnology space. Amarin Corporation plc is a Dublin-domiciled cardiovascular drugmaker with an approved, revenue-generating product, while MacroGenics, Inc. is a Maryland-based clinical-stage oncology company whose value hinges on experimental therapies. This stock comparison is most relevant to traders and investors assessing relative performance, market positioning, and how commercial stability stacks up against pipeline-driven upside in the current environment.
AMRN Overview and Recent Performance
AMRN commercializes Vascepa (known as Vazkepa in Europe), an icosapent ethyl therapy for cardiovascular risk reduction and elevated triglycerides. The company has been navigating a strategic transition, shifting to a partnered international model anchored by an exclusive agreement with Recordati covering dozens of European markets, while managing ongoing generic competition in the U.S.
Recent market activity reflects this turnaround phase. Amarin reported that it generated positive operating cash flow for a third consecutive quarter and ended its most recent quarter with more than $300 million in cash and no debt, even as total revenue declined year over year. The company also announced plans to reduce its total workforce by roughly 40%—including a deeper cut to its U.S. commercial team—as part of an effort to remove about $100 million in annual operating costs. European in-market demand has grown briskly, and Vascepa's U.S. prescription share has held steady, but recognized revenue and pricing pressure remain key watch items. Analyst sentiment has stayed cautious, with some firms reinstating coverage at underweight-equivalent ratings and price targets near or below recent trading levels.
MGNX Overview and Recent Performance
MGNX is a biotechnology company developing antibody-based cancer therapies built on its proprietary DART and TRIDENT platforms. Its pipeline includes lorigerlimab, a bispecific antibody targeting PD-1 and CTLA-4, as well as ADC candidates MGC026 and MGC028. The company also earns royalties and milestone payments through partnerships with Incyte, Sanofi, and Gilead, including the commercialized products ZYNYZ and TZIELD.
MacroGenics has been repositioning itself through two significant transactions: a monetization of future ZYNYZ royalties with Sagard Health, which brought in $60 million upfront, and a pending divestiture of its manufacturing operations to Bora Pharmaceuticals for about $122.5 million. Together these moves are designed to extend the company's cash runway through 2028. On the clinical side, the company faced a partial clinical hold on its LINNET study of lorigerlimab following serious safety events, and it discontinued development in one ovarian cancer indication. The shares delivered triple-digit year-to-date gains at one point but have retraced meaningfully in recent weeks, trading below key moving averages. Consensus analyst price targets remain above the current share price, reflecting the market's focus on forthcoming ADC data.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated destination where traders can explore a selection of AI-driven trading bots drawn from a much larger universe of hundreds of automated strategies trading thousands of different tickers. Because bots vary widely in trading style, strategy, timeframe, performance, and the specific securities they trade, only those best suited to current market conditions are surfaced in this section. The platform highlights key statistics—such as trade frequency, win rates, and historical performance ranges—so users can evaluate bots across different risk profiles and objectives. For investors following names like AMRN and MGNX, these tools offer a data-driven way to monitor momentum and positioning. Explore the Trending AI Robots page to review the strategies currently performing best in the market.
Head-to-Head Comparison
The core contrast between these two companies is one of business stage and revenue profile. AMRN has a single marketed asset generating consistent, if declining, cash flow, and its investment thesis centers on cost discipline, cash generation, and international expansion through partners. Its principal risks are single-product concentration, generic competition, and pricing and reimbursement pressure in the U.S.
MGNX, by contrast, is a clinical-stage company whose near-term revenue is modest and lumpy, driven largely by contract manufacturing and partnered royalties. Its value proposition is pipeline-driven: forthcoming ADC and bispecific data represent potential catalysts, but also binary risk, as evidenced by the recent clinical hold and discontinued indication. MacroGenics carries higher volatility and greater sensitivity to trial outcomes, while Amarin offers more stable—though slower-growing—fundamentals.
From a momentum standpoint, MacroGenics' shares have shown far larger swings in both directions, whereas Amarin has traded in a relatively contained range. Sector exposure also differs, with Amarin concentrated in cardiovascular care and MacroGenics in immuno-oncology.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and catalyst positioning, Tickeron's AI would likely favor AMRN in the current environment. Amarin's consistent positive operating cash flow, debt-free balance sheet, and defined cost-reduction plan offer a more stable trend profile, whereas MGNX carries elevated volatility tied to binary clinical readouts and a recent pullback below key technical levels. That said, MacroGenics' richer pipeline of potential catalysts and higher consensus upside means the comparison is not one-sided. The AI's relative preference should be interpreted as probabilistic rather than definitive, and it may shift as new clinical data, partnership developments, and momentum signals emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a StrongBuy and MGNX is a Hold.
AMRN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 38 cases where AMRN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Indicator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 70 cases where AMRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for AMRN just turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +2.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for AMRN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.561) is normal, around the industry mean (-2.730). P/E Ratio (-9.825) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
MGNX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 23, 2026
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 34 cases where MGNX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MGNX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 83 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.343) is normal, around the industry mean (3.043). P/E Ratio (-10.227) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AMRN | MGNX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 97 | |
PRICE GROWTH RATING 1..100 | 77 | 44 | |
P/E GROWTH RATING 1..100 | 26 | 9 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (68) in the Pharmaceuticals Other industry is in the same range as MGNX (88) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MGNX (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as MGNX (97) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for AMRN (77) in the Pharmaceuticals Other industry. This means that MGNX’s stock grew somewhat faster than AMRN’s over the last 12 months.
MGNX's P/E Growth Rating (9) in the Biotechnology industry is in the same range as AMRN (26) in the Pharmaceuticals Other industry. This means that MGNX’s stock grew similarly to AMRN’s over the last 12 months.
| AMRN | MGNX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 87% |
| Momentum ODDS (%) | 5 days ago 82% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 76% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 87% |
| Advances ODDS (%) | 1 day ago 73% | 3 days ago 85% |
| Declines ODDS (%) | 9 days ago 85% | 11 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while MGNX’s FA Score has 1 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- MGNX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 5 TA indicator(s) are bullish while MGNX’s TA Score has 4 bullish TA indicator(s).
- AMRN’s TA Score: 5 bullish, 3 bearish.
- MGNX’s TA Score: 4 bullish, 6 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а +4.15% price change this week, while MGNX (@Biotechnology) price change was -30.77% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
AMRN is expected to report earnings on Oct 28, 2026.
MGNX is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | +1.64% | ||
| CNTB - AMRN | 55% Loosely correlated | +0.58% | ||
| HRTX - AMRN | 44% Loosely correlated | +2.23% | ||
| MGNX - AMRN | 44% Loosely correlated | -38.02% | ||
| ALXO - AMRN | 43% Loosely correlated | -1.68% | ||
| ARWR - AMRN | 40% Loosely correlated | -0.58% | ||
More | ||||
MGNX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | -38.02% | ||
| KRRO - MGNX | 45% Loosely correlated | -0.58% | ||
| VYGR - MGNX | 44% Loosely correlated | -6.45% | ||
| AMRN - MGNX | 44% Loosely correlated | +1.64% | ||
| ZVRA - MGNX | 39% Loosely correlated | -5.03% | ||
| MLTX - MGNX | 34% Loosely correlated | -3.97% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TEK | 36.19 | 0.34 | +0.95% |
| iShares Technology Opportunities Active ETF | |||
| UXJL | 37.53 | N/A | N/A |
| FT Vest U.S. Equity Uncapped Accelerator ETF - July | |||
| MDYV | 92.06 | -0.40 | -0.43% |
| State Street SPDR S&P 400 Mid Cap Value ETF (MDYV) | |||
| TEQI | 52.53 | -0.32 | -0.60% |
| T. Rowe Price Equity Income ETF (TEQI) | |||
| SPVM | 76.55 | -0.68 | -0.88% |
| Invesco S&P 500 Value with Momentum ETF (SPVM) | |||